Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells

Yasuyuki Fukuhara, Xiao Kang Li, Yusuke Kitazawa, Masumi Inagaki, Kentaro Matsuoka, Motomichi Kosuga, Rika Kosaki, Takuya Shimazaki, Hitoshi Endo, Akihiro Umezawa, Hideyuki Okano, Takao Takahashi, Torayuki Okuyama

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The therapeutic efficacy of neural stem cell transplantation for central nervous system (CNS) lesions in lysosomal storage disorders was explored using a murine model of mucopolysaccharidosis type VII (MPS VII). We used fetal neural stem cells derived from embryonic mouse striata and expanded in vitro by neurosphere formation as the source of graft materials. We transplanted neurospheres into the lateral ventricles of newborn MPS VII mice and found that donor cells migrated far beyond the site of injection within 24 h, and some of them could reach the olfactory bulb. A quantitative measurement indicated that the GUSB activity in the brain was 12.5 to 42.3% and 5.5 to 6.3% of normal activity at 24 h and 3 weeks after transplantation. In addition, histological analysis revealed a widespread decrease in lysosomal storage in the recipient's hippocampus, cortex, and ependyma. A functional assessment with novel-object recognition tests confirmed improvements in behavioral patterns. These results suggest that intracerebral transplantation of neural stem cells is feasible for treatment of CNS lesions associated with lysosomal storage disorders.

Original languageEnglish
Pages (from-to)548-555
Number of pages8
JournalMolecular Therapy
Volume13
Issue number3
DOIs
Publication statusPublished - 2006 Mar

Fingerprint

Mucopolysaccharidosis VII
Neural Stem Cells
Transplantation
Central Nervous System
Fetal Stem Cells
Ependyma
Lateral Ventricles
Olfactory Bulb
Stem Cell Transplantation
Hippocampus
Transplants
Injections
Brain
Therapeutics

Keywords

  • Intracerebral transplantation
  • Mucopolysaccharidosis type VII
  • Neurosphere

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells. / Fukuhara, Yasuyuki; Li, Xiao Kang; Kitazawa, Yusuke; Inagaki, Masumi; Matsuoka, Kentaro; Kosuga, Motomichi; Kosaki, Rika; Shimazaki, Takuya; Endo, Hitoshi; Umezawa, Akihiro; Okano, Hideyuki; Takahashi, Takao; Okuyama, Torayuki.

In: Molecular Therapy, Vol. 13, No. 3, 03.2006, p. 548-555.

Research output: Contribution to journalArticle

Fukuhara, Yasuyuki ; Li, Xiao Kang ; Kitazawa, Yusuke ; Inagaki, Masumi ; Matsuoka, Kentaro ; Kosuga, Motomichi ; Kosaki, Rika ; Shimazaki, Takuya ; Endo, Hitoshi ; Umezawa, Akihiro ; Okano, Hideyuki ; Takahashi, Takao ; Okuyama, Torayuki. / Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells. In: Molecular Therapy. 2006 ; Vol. 13, No. 3. pp. 548-555.
@article{8d346245350f4738a73e2b19e08955a6,
title = "Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells",
abstract = "The therapeutic efficacy of neural stem cell transplantation for central nervous system (CNS) lesions in lysosomal storage disorders was explored using a murine model of mucopolysaccharidosis type VII (MPS VII). We used fetal neural stem cells derived from embryonic mouse striata and expanded in vitro by neurosphere formation as the source of graft materials. We transplanted neurospheres into the lateral ventricles of newborn MPS VII mice and found that donor cells migrated far beyond the site of injection within 24 h, and some of them could reach the olfactory bulb. A quantitative measurement indicated that the GUSB activity in the brain was 12.5 to 42.3{\%} and 5.5 to 6.3{\%} of normal activity at 24 h and 3 weeks after transplantation. In addition, histological analysis revealed a widespread decrease in lysosomal storage in the recipient's hippocampus, cortex, and ependyma. A functional assessment with novel-object recognition tests confirmed improvements in behavioral patterns. These results suggest that intracerebral transplantation of neural stem cells is feasible for treatment of CNS lesions associated with lysosomal storage disorders.",
keywords = "Intracerebral transplantation, Mucopolysaccharidosis type VII, Neurosphere",
author = "Yasuyuki Fukuhara and Li, {Xiao Kang} and Yusuke Kitazawa and Masumi Inagaki and Kentaro Matsuoka and Motomichi Kosuga and Rika Kosaki and Takuya Shimazaki and Hitoshi Endo and Akihiro Umezawa and Hideyuki Okano and Takao Takahashi and Torayuki Okuyama",
year = "2006",
month = "3",
doi = "10.1016/j.ymthe.2005.09.020",
language = "English",
volume = "13",
pages = "548--555",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Histopathological and behavioral improvement of murine mucopolysaccharidosis type VII by intracerebral transplantation of neural stem cells

AU - Fukuhara, Yasuyuki

AU - Li, Xiao Kang

AU - Kitazawa, Yusuke

AU - Inagaki, Masumi

AU - Matsuoka, Kentaro

AU - Kosuga, Motomichi

AU - Kosaki, Rika

AU - Shimazaki, Takuya

AU - Endo, Hitoshi

AU - Umezawa, Akihiro

AU - Okano, Hideyuki

AU - Takahashi, Takao

AU - Okuyama, Torayuki

PY - 2006/3

Y1 - 2006/3

N2 - The therapeutic efficacy of neural stem cell transplantation for central nervous system (CNS) lesions in lysosomal storage disorders was explored using a murine model of mucopolysaccharidosis type VII (MPS VII). We used fetal neural stem cells derived from embryonic mouse striata and expanded in vitro by neurosphere formation as the source of graft materials. We transplanted neurospheres into the lateral ventricles of newborn MPS VII mice and found that donor cells migrated far beyond the site of injection within 24 h, and some of them could reach the olfactory bulb. A quantitative measurement indicated that the GUSB activity in the brain was 12.5 to 42.3% and 5.5 to 6.3% of normal activity at 24 h and 3 weeks after transplantation. In addition, histological analysis revealed a widespread decrease in lysosomal storage in the recipient's hippocampus, cortex, and ependyma. A functional assessment with novel-object recognition tests confirmed improvements in behavioral patterns. These results suggest that intracerebral transplantation of neural stem cells is feasible for treatment of CNS lesions associated with lysosomal storage disorders.

AB - The therapeutic efficacy of neural stem cell transplantation for central nervous system (CNS) lesions in lysosomal storage disorders was explored using a murine model of mucopolysaccharidosis type VII (MPS VII). We used fetal neural stem cells derived from embryonic mouse striata and expanded in vitro by neurosphere formation as the source of graft materials. We transplanted neurospheres into the lateral ventricles of newborn MPS VII mice and found that donor cells migrated far beyond the site of injection within 24 h, and some of them could reach the olfactory bulb. A quantitative measurement indicated that the GUSB activity in the brain was 12.5 to 42.3% and 5.5 to 6.3% of normal activity at 24 h and 3 weeks after transplantation. In addition, histological analysis revealed a widespread decrease in lysosomal storage in the recipient's hippocampus, cortex, and ependyma. A functional assessment with novel-object recognition tests confirmed improvements in behavioral patterns. These results suggest that intracerebral transplantation of neural stem cells is feasible for treatment of CNS lesions associated with lysosomal storage disorders.

KW - Intracerebral transplantation

KW - Mucopolysaccharidosis type VII

KW - Neurosphere

UR - http://www.scopus.com/inward/record.url?scp=32944454488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944454488&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.09.020

DO - 10.1016/j.ymthe.2005.09.020

M3 - Article

C2 - 16316785

AN - SCOPUS:32944454488

VL - 13

SP - 548

EP - 555

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -